Recent advances in cancer immunotherapy extend beyond PD-1/PD-L1 blockade to include novel checkpoint targets (e.g., LAG-3, TIGIT), engineered cellular therapies, and strategies to remodel the tumor microenvironment (TME)—strategies increasingly relevant to esophageal cancer (14, 26). Here, PDCD1 is linked to neoplasm.